Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
tACS to Enhance Language Abilities
NCT06092814
Recruiting
The goal of this study is to see if transcranial alternating current stimulation (tACS) can be used to enhance language abilities in people with post-stroke aphasia. Participants will receive real and sham tACS in conjunction with various language tests. Researchers will compare the post-stroke aphasia group with aged matched controls to see if brain response to tACS differs between groups.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Stroke, Aphasia, Acquired, Aphasia
Register for Updates
Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT06067802
Recruiting
This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with MCADD.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/04/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Register for Updates
Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea
NCT06008626
Recruiting
This is a prospective, multicenter, non-randomized single-arm safety and performance study to collect data to evaluate the safety of the Cryosa procedure to treat obstructive sleep apnea (OSA) in patients with moderate to severe OSA. The study will also evaluate the chronic performance of the Cryosa system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
08/04/2025
Locations: Specialty Physician Associates, Bethlehem, Pennsylvania
Conditions: Obstructive Sleep Apnea of Adult
Register for Updates
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501
Recruiting
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: third line or later of treatment (3L) + chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Pennsylvania /ID# 250341, Philadelphia, Pennsylvania
Conditions: Hematologic Cancer
Register for Updates
Pilot/Pivotal Study of DBS+Rehab After Stroke
NCT05701280
Recruiting
The RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating arm weakness and reduced function after a stroke.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/04/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Stroke, Upper Extremity Paresis
Register for Updates
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
NCT05686317
Recruiting
This is a prospective, multi-center, randomized, sham-controlled, double-blinded (participant and outcomes assessor) clinical trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Lankenau Medical Center, Wynnewood, Pennsylvania
Conditions: Heart Failure
Register for Updates
Promoting Positive Care Interactions (PPCI) in Assisted Living
NCT05618834
Recruiting
The overall aim of this study is to pilot test Promoting Positive Care Interactions (PPCI) with the goal of establishing a feasible and culturally responsive approach to optimize care interactions between staff (nursing, activity, housekeeping, and dining service staff) and residents with ADRD in assisted living facilities (ALFs), and further improve select resident, staff, and facility outcomes. PPCI is a non- pharmacological four-step approach consisting of (1) stakeholder engagement in develo... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/04/2025
Locations: The Pennsylvania State University, University Park, Pennsylvania
Conditions: Alzheimer Disease and Related Dementias
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: 84000234 - Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
NCT05416307
Recruiting
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/04/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Register for Updates
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613
Recruiting
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
08/04/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Mucopolysaccharidosis II
Register for Updates
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
NCT05295290
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who: 1. Are age \<21 years. 2. Have presentation to participating medical center with evaluation in Emergency Room and/or hospitalization. 3. Received either the 1st, 2nd, 3rd or booster dose(s) of COMIRNATY within 7 days of symptom onset. 4. Meet criteria of Centers for Disease Control and Prevention cas... Read More
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
08/04/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Myocarditis
Register for Updates
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in grou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Thomas Jefferson University Hospital /ID# 242077, Philadelphia, Pennsylvania
Conditions: Non-Hodgkin Lymphoma
Register for Updates